Literature DB >> 26920639

Pen Devices for Insulin Self-Administration Compared With Needle and Vial: Systematic Review of the Literature and Meta-Analysis.

Pieralessandro Lasalvia1, Julián Esteban Barahona-Correa1, Diana Marcela Romero-Alvernia1, Sebastián Gil-Tamayo1, Camilo Castañeda-Cardona2, Juan Gabriel Bayona1, Juan José Triana1, Andrés Felipe Laserna1, Miguel Mejía-Torres1, Paula Restrepo-Jimenez1, Juliana Jimenez-Zapata1, Diego Rosselli3.   

Abstract

OBJECTIVES: Pen devices offer advantages compared with vial and syringe (VaS). The purpose of this article was to evaluate efficacy of pen devices compared to VaS.
METHODS: A systematic review of literature was performed in 8 different databases. References were independently screened and selected. Primary observational or experimental studies comparing pen devices with VaS for insulin administrations were included. Studies on specific populations were excluded. Risk of bias was evaluated using appropriate tools. Data on glycosylated hemoglobin (HbA1c), hypoglycemia, adherence, persistence, patient preference, and quality of life (QOL) were collected. Meta-analysis was performed when appropriate. Heterogeneity and risk of publication bias were evaluated. Otherwise, descriptive analyses of the available data was done.
RESULTS: In all, 10 348 articles were screened. A total of 17 studies were finally selected: 7 experimental and 10 analytical. The populations of the included articles were mainly composed of adults with type 2 diabetes mellitus. Important risk of bias was found in all of the articles, particularly experimental studies. Meta-analyses were performed for HbA1c, hypoglycemia, adherence and persistence. Pen device showed better results in mean HbA1c change, patients with hypoglycemia, adherence and persistence compared to VaS. No difference was observed in number of patients achieving <7% HbA1c. Preference studies showed a tendency favoring pen devices, however nonvalidated tools were used. One QoL study showed improvements in some subscales of SF-36.
CONCLUSIONS: There is evidence that pen devices offer benefits in clinical and, less clearly, patient-reported outcomes compared to VaS for insulin administration. However, these results should be taken with caution.
© 2016 Diabetes Technology Society.

Entities:  

Keywords:  diabetes mellitus; equipment and supplies; glycosylated; hemoglobin A; insulin; medication adherence; patient preference

Mesh:

Substances:

Year:  2016        PMID: 26920639      PMCID: PMC4928229          DOI: 10.1177/1932296816633721

Source DB:  PubMed          Journal:  J Diabetes Sci Technol        ISSN: 1932-2968


  25 in total

1.  Adherence and persistence to a regimen of basal insulin in a pre-filled pen compared to vial/syringe in insulin-naïve patients with type 2 diabetes.

Authors:  Erin Buysman; Christopher Conner; Mark Aagren; Jonathan Bouchard; Fang Liu
Journal:  Curr Med Res Opin       Date:  2011-07-11       Impact factor: 2.580

2.  Clinical and economic outcomes among patients with diabetes mellitus initiating insulin glargine pen versus vial.

Authors:  Michael Grabner; James Chu; Swetha Raparla; Ralph Quimbo; Steve Zhou; Joseph Conoshenti
Journal:  Postgrad Med       Date:  2013-05       Impact factor: 3.840

3.  Medication adherence and the associated health-economic impact among patients with type 2 diabetes mellitus converting to insulin pen therapy: an analysis of third-party managed care claims data.

Authors:  Won Chan Lee; Sanjeev Balu; David Cobden; Ashish V Joshi; Chris L Pashos
Journal:  Clin Ther       Date:  2006-10       Impact factor: 3.393

Review 4.  Evolution of diabetes insulin delivery devices.

Authors:  Jean-Louis Selam
Journal:  J Diabetes Sci Technol       Date:  2010-05-01

5.  Effect of glargine insulin delivery method (pen device versus vial/syringe) on glycemic control and patient preferences in patients with type 1 and type 2 diabetes.

Authors:  Stacey A Seggelke; R Matthew Hawkins; Joanna Gibbs; Neda Rasouli; Cecilia C Low Wang; Boris Draznin
Journal:  Endocr Pract       Date:  2014-06       Impact factor: 3.443

Review 6.  Assessment of patient-reported outcomes of insulin pen devices versus conventional vial and syringe.

Authors:  Cliff Molife; Lauren J Lee; Lizheng Shi; Monika Sawhney; Sheila M Lenox
Journal:  Diabetes Technol Ther       Date:  2009-08       Impact factor: 6.118

7.  Improvement in health-related quality of life, independent of fasting glucose concentration, via insulin pen device in diabetic patients.

Authors:  I-Te Lee; Hsiu-Chen Liu; Yi-Ju Liau; Wen-Jane Lee; Chien-Ning Huang; Wayne Huey-Herng Sheu
Journal:  J Eval Clin Pract       Date:  2009-08       Impact factor: 2.431

8.  Adherence to premixed insulin in a prefilled pen compared with a vial/syringe in people with diabetes in Singapore.

Authors:  Hua Heng McVin Cheen; Seng Han Lim; Ming Chien Huang; Yong Mong Bee; Hwee Lin Wee
Journal:  Clin Ther       Date:  2014-06-07       Impact factor: 3.393

9.  A multicenter, randomized, open-label, comparative, two-period crossover trial of preference, efficacy, and safety profiles of a prefilled, disposable pen and conventional vial/syringe for insulin injection in patients with type 1 or 2 diabetes mellitus.

Authors:  Mary Korytkowski; David Bell; Carol Jacobsen; Rudee Suwannasari
Journal:  Clin Ther       Date:  2003-11       Impact factor: 3.393

10.  A general method of compliance assessment using centralized pharmacy records. Description and validation.

Authors:  J F Steiner; T D Koepsell; S D Fihn; T S Inui
Journal:  Med Care       Date:  1988-08       Impact factor: 2.983

View more
  13 in total

1.  Advances in Care for Insulin-Requiring Patients Without Closed Loop.

Authors:  Rayhan A Lal; Bruce Buckingham; David M Maahs
Journal:  Diabetes Technol Ther       Date:  2018-06       Impact factor: 6.118

2.  Smart Pens Will Improve Insulin Therapy.

Authors:  David C Klonoff; David Kerr
Journal:  J Diabetes Sci Technol       Date:  2018-02-07

Review 3.  Management of hyperglycaemia in type 2 diabetes, 2022. A consensus report by the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD).

Authors:  Melanie J Davies; Vanita R Aroda; Billy S Collins; Robert A Gabbay; Jennifer Green; Nisa M Maruthur; Sylvia E Rosas; Stefano Del Prato; Chantal Mathieu; Geltrude Mingrone; Peter Rossing; Tsvetalina Tankova; Apostolos Tsapas; John B Buse
Journal:  Diabetologia       Date:  2022-09-24       Impact factor: 10.460

4.  Can Smart Pens Help Improve Diabetes Management?

Authors:  Sarah L Sy; Medha M Munshi; Elena Toschi
Journal:  J Diabetes Sci Technol       Date:  2020-10-21

5.  Management of hyperglycaemia in type 2 diabetes, 2018. A consensus report by the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD).

Authors:  Melanie J Davies; David A D'Alessio; Judith Fradkin; Walter N Kernan; Chantal Mathieu; Geltrude Mingrone; Peter Rossing; Apostolos Tsapas; Deborah J Wexler; John B Buse
Journal:  Diabetologia       Date:  2018-12       Impact factor: 10.122

6.  Vial-to-Pen: Community-Based Pharmacists Converting Insulin Regimens.

Authors:  Ashley N Hannings; Natasha M Michaels; Debbie Hiller; Macary Weck Marciniak; Stefanie P Ferreri
Journal:  Innov Pharm       Date:  2019-07-08

7.  Smart Insulin Pens: Advancing Digital Transformation and a Connected Diabetes Care Ecosystem.

Authors:  Tejaswi Kompala; Aaron B Neinstein
Journal:  J Diabetes Sci Technol       Date:  2021-01-12

8.  Dose Accuracy, Injection Force, and Usability Assessment of a New Half-Unit, Prefilled Insulin Pen.

Authors:  Christopher M Kappes; James R Kershner; Tina M Morwick; Sheila M Corrigan
Journal:  J Diabetes Sci Technol       Date:  2017-10-30

9.  Management of Hyperglycemia in Type 2 Diabetes, 2018. A Consensus Report by the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD).

Authors:  Melanie J Davies; David A D'Alessio; Judith Fradkin; Walter N Kernan; Chantal Mathieu; Geltrude Mingrone; Peter Rossing; Apostolos Tsapas; Deborah J Wexler; John B Buse
Journal:  Diabetes Care       Date:  2018-10-04       Impact factor: 19.112

Review 10.  Leveraging advances in diabetes technologies in primary care: a narrative review.

Authors:  Bruce Bode; Aaron King; David Russell-Jones; Liana K Billings
Journal:  Ann Med       Date:  2021-12       Impact factor: 4.709

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.